A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

[1]  Jeon-Soo Shin,et al.  Double‐stranded RNA mediates interferon regulatory factor 3 activation and interleukin‐6 production by engaging Toll‐like receptor 3 in human brain astrocytes , 2008, Immunology.

[2]  T. Seya,et al.  TLR3: interferon induction by double-stranded RNA including poly(I:C). , 2008, Advanced drug delivery reviews.

[3]  A. Hovanessian On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2'-5'oligoadenylate synthetases and the protein kinase PKR. , 2007, Cytokine & growth factor reviews.

[4]  Junichi Eguchi,et al.  Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models , 2007, Journal of Translational Medicine.

[5]  G. Barber,et al.  PKR in innate immunity, cancer, and viral oncolysis. , 2007, Methods in molecular biology.

[6]  R. Silverman,et al.  Tumour suppressor function of RNase L in a mouse model. , 2007, European journal of cancer.

[7]  R. G. van der Most,et al.  Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. , 2006, Cancer research.

[8]  M. Morse,et al.  Combining cancer vaccines with chemotherapy , 2005, Expert opinion on pharmacotherapy.

[9]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[10]  Keith L Black,et al.  Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.

[11]  R. Dick,et al.  Sensitivities of human glioma cell lines to interferons and double-stranded RNAs individually and in synergistic combinations , 2004, Journal of Neuro-Oncology.

[12]  M. Adamo,et al.  Double-stranded ribonucleic acid decreases c6 rat glioma cell proliferation in part by activating protein kinase R and decreasing insulin-like growth factor I levels. , 2002, Endocrinology.

[13]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[14]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Radosevich,et al.  Interferon-Responsive Protein Kinase (p68) and Proliferating Cell Nuclear Antigen Are Inversely Distributed in Head and Neck Squamous Cell Carcinoma , 1997, Tumor Biology.

[16]  A. Ommaya,et al.  Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. , 1996, Neurosurgery.

[17]  M. Mathews,et al.  Activation of the double-stranded RNA (dsRNA)-activated human protein kinase in vivo in the absence of its dsRNA binding domain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Graham Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[19]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[20]  M. Katze,et al.  Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Talmadge,et al.  Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC]. , 1992, International journal of immunopharmacology.

[22]  K. Black,et al.  Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. , 1992, Journal of neurosurgery.

[23]  D. Longo,et al.  Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. , 1992, Cancer research.

[24]  A. Hovanessian Interferon-induced and double-stranded RNA-activated enzymes: a specific protein kinase and 2',5'-oligoadenylate synthetases. , 1991, Journal of interferon research.

[25]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Yung,et al.  Growth Inhibitory Effects of Interferon-β but Not Interferon-α on Human Glioma Cells: Correlation of Receptor Binding, 2′,5′-O1igoadenylate Synthetase and Protein Kinase Activity , 1990 .

[27]  M. Katze,et al.  The binding of double-stranded RNA and adenovirus VAI RNA to the interferon-induced protein kinase. , 1989, European journal of biochemistry.

[28]  A. Cook,et al.  Growth of Astrocytomas in the Human Tumor Clonogenic Assay and Sensitivity to Mismatched dsRNA and Interferons , 1987, American journal of clinical oncology.

[29]  N. Bleehen,et al.  An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. , 1987, British Journal of Cancer.

[30]  M. Droller Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid. , 1987, The Journal of urology.

[31]  P. Disaia,et al.  Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)). , 1986, Gynecologic oncology.

[32]  G. Hortobagyi,et al.  Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. , 1986, Cancer treatment reports.

[33]  E. Borden,et al.  An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. , 1985, Journal of biological response modifiers.

[34]  W. Stewart,et al.  Phase I trials of poly(I,C) complexes in advanced cancer. , 1985, Journal of biological response modifiers.

[35]  K. Foon,et al.  Immunomodulatory effects of poly(I,C)-LC in cancer patients. , 1985, Journal of biological response modifiers.

[36]  Levy Hb Historical overview of the use of polynucleotides in cancer. , 1985 .

[37]  J. Adams,et al.  Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. , 1985, Journal of immunology.

[38]  J. Talmadge,et al.  Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. , 1985, Cancer research.

[39]  H. Levy Historical overview of the use of polynucleotides in cancer. , 1985, Journal of biological response modifiers.

[40]  H. Hubbell,et al.  Independent sensitivity of human tumor cell lines to interferon and double-stranded RNA. , 1984, Cancer research.

[41]  K. Takakura,et al.  Phase I-II trials of poly(ICLC) in malignant brain tumor patients. , 1982, Journal of interferon research.

[42]  Levine As,et al.  Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man. , 1981 .

[43]  A. Levine,et al.  Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man. , 1981, Texas reports on biology and medicine.

[44]  A. Anderson,et al.  IMMUNE MODULATING EFFECTS OF POLY ICLC , 1980, Annals of the New York Academy of Sciences.

[45]  C. Baglioni,et al.  Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. , 1979, The Journal of biological chemistry.